-$0.64 Earnings Per Share Expected for Tetraphase Pharmaceuticals Inc (TTPH) This Quarter
Wall Street brokerages forecast that Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) will report ($0.64) earnings per share (EPS) for the current quarter, according to Zacks. Three analysts have made estimates for Tetraphase Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.69) and the highest is ($0.60). Tetraphase Pharmaceuticals reported earnings of ($0.61) per share in the same quarter last year, which indicates a negative year over year growth rate of 4.9%. The firm is expected to report its next earnings results on Wednesday, March 14th.
According to Zacks, analysts expect that Tetraphase Pharmaceuticals will report full-year earnings of ($2.88) per share for the current fiscal year, with EPS estimates ranging from ($2.95) to ($2.80). For the next financial year, analysts expect that the company will post earnings of ($2.20) per share, with EPS estimates ranging from ($2.63) to ($1.75). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that follow Tetraphase Pharmaceuticals.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) EPS for the quarter, hitting analysts’ consensus estimates of ($0.63). Tetraphase Pharmaceuticals had a negative net margin of 1,382.33% and a negative return on equity of 88.27%. The business had revenue of $4.10 million for the quarter, compared to analyst estimates of $1.59 million. During the same period last year, the business posted ($0.58) earnings per share. The firm’s quarterly revenue was up 355.6% on a year-over-year basis.
Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded down $0.25 during trading hours on Tuesday, hitting $6.26. 345,646 shares of the company were exchanged, compared to its average volume of 447,730. Tetraphase Pharmaceuticals has a fifty-two week low of $3.57 and a fifty-two week high of $9.93. The firm has a market capitalization of $321.86, a price-to-earnings ratio of -2.18 and a beta of 2.51.
In other Tetraphase Pharmaceuticals news, Director L Patrick Gage bought 3,880 shares of the firm’s stock in a transaction that occurred on Wednesday, November 29th. The stock was acquired at an average price of $6.45 per share, with a total value of $25,026.00. Following the completion of the transaction, the director now owns 38,880 shares in the company, valued at $250,776. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jacques Dumas sold 7,167 shares of the firm’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $6.21, for a total transaction of $44,507.07. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in the stock. Canada Pension Plan Investment Board grew its position in Tetraphase Pharmaceuticals by 54.4% in the third quarter. Canada Pension Plan Investment Board now owns 2,554,100 shares of the biopharmaceutical company’s stock valued at $17,470,000 after purchasing an additional 900,000 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Tetraphase Pharmaceuticals by 32.7% in the third quarter. Dimensional Fund Advisors LP now owns 1,461,807 shares of the biopharmaceutical company’s stock valued at $9,998,000 after purchasing an additional 360,552 shares in the last quarter. JPMorgan Chase & Co. bought a new position in Tetraphase Pharmaceuticals in the third quarter valued at $7,915,000. Northern Trust Corp grew its position in Tetraphase Pharmaceuticals by 4.8% in the second quarter. Northern Trust Corp now owns 886,765 shares of the biopharmaceutical company’s stock valued at $6,323,000 after purchasing an additional 40,668 shares in the last quarter. Finally, Numeric Investors LLC grew its position in Tetraphase Pharmaceuticals by 1,363.3% in the second quarter. Numeric Investors LLC now owns 754,364 shares of the biopharmaceutical company’s stock valued at $5,379,000 after purchasing an additional 702,812 shares in the last quarter. 58.15% of the stock is owned by institutional investors and hedge funds.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.